Jumping ahead of Merck and others, Bristol Myers declares a PD-1 first in NSCLC
Bristol Myers Squibb said this morning they cleared a PD-1 hurdle, showing for the first time that a checkpoint can clear tumors in early-stage lung cancer patients before surgery.
The company announced this morning that Opdivo hit one of two primary endpoints on Checkmate-816. In the 350-person study, non-small cell lung cancer patients who received the PD-(L)1 blocker before surgery were significantly more likely to show no evidence of cancer than patients who received chemotherapy.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
